Study reveals that chemotherapy works in an unexpected way

April 4, 2013

It's generally thought that anticancer chemotherapies work like antibiotics do, by directly killing off what's harmful. But new research published online on April 4 in the Cell Press journal Immunity shows that effective chemotherapies actually work by mobilizing the body's own immune cells to fight cancer. Researchers found that chemo-treated dying tumors secrete a factor that attracts certain immune cells, which then ingest tumor proteins and present them on their surfaces as alert signals that an invader is present. This new understanding of how chemotherapy works with our immune systems could prompt new tactics for treating cancer.

"Successful chemotherapeutics convert the tumor into a , hence mobilizing the host's immune system against the cancer," explains senior author Dr. Guido Kroemer, of the Institut Gustave Roussy, in France.

Dr. Kroemer and his colleagues found that when chemotherapy kills and bursts open , the cells release a factor called ATP. The factor recruits to the tumor site, where they are educated to acquire their function—namely, to ingest and present tumor proteins on their surfaces. The researchers found that when these trained immune cells are blocked, chemotherapy (specifically, anthracyclines) cannot efficiently reduce the growth of tumors in mice. Also, when these trained immune cells are injected into other mice, the mice can fight off cancer cells that are subsequently injected.

The findings point to a new strategy to improve cancer treatments. "Anticancer therapies and immunotherapies might be combined in a way to optimize the local recruitment and function of immune cells—for instance, by increasing extracellular ATP levels—with the goal of boosting the chemotherapy-induced anticancer immune response," says Dr. Kroemer. Also, measuring the recruitment of immune cells to tumor sites after chemotherapy might help predict how well a patient's cancer will respond to the treatment.

Explore further: Mechanism for esophageal cancer uncovered

More information: Immunity, Ma et al.: "Anticancer chemotherapy induced intratumoral recruitment and differentiation of antigen presenting cells." dx.doi.org/10.1016/j.immuni.2013.03.003

Related Stories

Mechanism for esophageal cancer uncovered

April 11, 2011

A gene thought to be associated with cancer development can be a tumor suppressor gene in mice, researchers have discovered. Understanding which genes are involved in spreading cancer could lead to future therapies.

Tumor environment keeps tumor-fighting T cells away

September 19, 2011

Tumors have an arsenal of tricks to help them sidestep the immune system. A study published on September 19 in the Journal of Experimental Medicine reveals a new trick -- the ability to keep tumor-fighting T cells out by ...

Immune-response genes affecting breast tumor eradication

May 3, 2012

Breast cancer patients whose tumors express high levels of genes related to immune response are more likely to have their tumor completely eradicated by pre-operative chemotherapy compared to patients with low expression ...

Recommended for you

Epigenomic changes are key to innate immunological memory

August 31, 2015

A research team led by Keisuke Yoshida and Shunsuke Ishii of the RIKEN Molecular Genetics Laboratory has revealed that epigenomic changes induced by pathogen infections, mediated by a transcription factor called ATF7, are ...

Team finds early inflammatory response paralyzes T cells

August 18, 2015

In a discovery that is likely to rewrite immunology text books, researchers at UC Davis have found that early exposure to inflammatory cytokines, such as interleukin 2, can "paralyze" CD4 T cells, immune components that help ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.